Eagle Rock Investment Company LLC Sells 164,375 Shares of Pfizer Inc. (NYSE:PFE)

Eagle Rock Investment Company LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 58.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 117,972 shares of the biopharmaceutical company's stock after selling 164,375 shares during the quarter. Eagle Rock Investment Company LLC's holdings in Pfizer were worth $3,130,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Gladius Capital Management LP raised its position in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP acquired a new stake in Pfizer during the 2nd quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer in the third quarter valued at approximately $35,000. Joseph Group Capital Management boosted its holdings in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 771 shares during the period. Finally, Kennebec Savings Bank bought a new stake in shares of Pfizer during the third quarter worth $50,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price on the stock. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

Pfizer Stock Performance

PFE stock traded down $0.19 during trading hours on Friday, reaching $26.30. The stock had a trading volume of 35,146,711 shares, compared to its average volume of 33,531,398. The stock has a 50-day simple moving average of $26.09 and a 200 day simple moving average of $28.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market capitalization of $149.06 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer's revenue was up 31.2% on a year-over-year basis. During the same period last year, the business posted ($0.17) EPS. Analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer's payout ratio is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.